Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Enrolling by invitation

Conditions studied: Blau Syndrome

In brief

To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.

Key facts

Study ID

NCT06688838

Run by

Tongji Hospital

People needed

24

Starts

2017-01-01

Expected to finish

2026-12-31

Last updated by the study team

2026-01-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must conform to the characteristic triad of granulomatous arthritis, uveitis, and dermatitis, or the characteristic non-caseous granuloma of BS indicated by skin or synovial biopsy;
• Whole exon detection indicated characteristic mutations of NOD2 gene

You may not qualify if…

• Patients with autoimmune diseases, including but not limited to lupus erythematosus, Sjogren's syndrome, vasculitis, ankylosing spondylitis, myositis, dermatomyositis, rheumatoid arthritis, etc.;
• combined with other neoplastic diseases, such as lymphoma, leukemia, etc.

Where it is running

• Yikai YU — Wuhan, Hubei, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.